SPRB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Spruce Biosciences Inc (SPRB) is not a strong buy at the moment for a beginner investor with a long-term strategy. The lack of positive financial performance, absence of significant trading trends, and neutral sentiment from hedge funds and insiders suggest limited immediate upside. Additionally, the technical indicators and options data do not provide a compelling entry point.
The stock's MACD is slightly positive at 0.0745, indicating weak bullish momentum. However, the RSI is neutral at 35.134, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support is at 50.261, with resistance at 55.777. Overall, the technicals do not strongly favor a buy.
The company is developing tralesinidase alfa enzyme replacement therapy, which has potential for accelerated review and peak sales of over $150M in the U.S. alone. Analysts maintain a Buy rating with a reduced price target of $200, indicating long-term potential.
Additionally, there is no recent news or significant trading activity to drive the stock upward.
In Q3 2025, the company's financials showed a significant decline: revenue dropped to 0 (-100% YoY), net income fell to -$8.21M (-5.29% YoY), and EPS decreased to -14.58 (-7.43% YoY). Gross margin also dropped to 0 (-100% YoY).
Analysts maintain a Buy rating but have lowered the price target from $220 to $200 due to delays in the enzyme replacement therapy filing. The long-term potential for the therapy remains positive, but the timeline has been pushed back.
